Ra Pharmaceuticals   Report issue

For profit Phase 3
Founded: Cambridge MA United States (2008)
Status: Acquired by UCB (2019)

Organization Overview

First Clinical Trial
2017
NCT03030183
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Ra Pharmaceuticals